Outcomes of Revision Cochlear Implantation.


Journal

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
ISSN: 1537-4505
Titre abrégé: Otol Neurotol
Pays: United States
ID NLM: 100961504

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 31 5 2020
medline: 15 4 2021
entrez: 31 5 2020
Statut: ppublish

Résumé

This study aims to 1) report revision cochlear implantation (CI) rates at a high-volume CI center, 2) describe classifications for revision CI, 3) analyze audiologic and surgical outcomes in patients who undergo revision CI, and 4) describe a new subcategory of soft failures, named presumed soft failures. Retrospective case series. Tertiary care otologic center. Adults and children undergoing revision CI from 2005 to 2015. Type and etiology of CI failure, preoperative, and postoperative outcomes (audiologic, surgical). During the study period, 1,469 CI surgeries were performed with a total of 81 (5.51%) revision cochlear implantations, 64 of these meeting inclusion criteria with adequate follow up and clear indications for revision surgery. The most common indication for revision surgery was hard failure (53.1%), followed by soft failure (29.7%), and medical/surgical failure (17.2%). 78.1% (50/64) of revision CI patients showed improvement postoperatively (defined as 15% improvement of speech perceptions scores or improvement of aversive symptoms, according to the 2005 consensus statement guidelines). Hard failures showed improvement in 85.3% (29/34) of cases, medical and surgical failures showed improvement in 72.7% (8/11) of cases, and soft failures showed improvement in 68.4% (13/19) of cases. There was a statistically significant difference in percentage of adult versus pediatric patients by failure subtype, with 84.2% of soft failure patients classified as adults (18 or older) at the time of revision surgery compared with 50% and 36.3% for hard failure and medical/surgical failure patients, respectively (p = 0.02). Similarly, there was a trend, though not statistically significant, towards older age in the soft failure group compared with hard and medical/surgical failure groups (median 43 yr versus 18 and 16, respectively). Within the soft failure group there was a subset of patients that failed to show improvement in audiologic performance or experienced continued aversive symptoms referred to as "presumed soft failures." These patients, by definition, experienced worse outcomes after revision surgery (p < 0.05) and trended towards older age (43 versus 31 yr) and longer time from initial to revision surgery (27.3 versus 24.7 mo) when compared with true soft failures. The majority of patients improved after revision CI surgery; patients with hard failure demonstrated the highest percentage with improvement, while those with soft failures had worse outcomes. The presumed soft failure group may represent a unique etiology for CI failure that warrants further investigation given worse outcomes after revision surgery.

Identifiants

pubmed: 32472921
doi: 10.1097/MAO.0000000000002659
pii: 00129492-202007000-00019
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e705-e711

Références

House LR. Cochlear implant: the beginning. Laryngoscope 1987; 97 (8 pt 1):996–997.
Mudry A, Mills M. The early history of the cochlear implant: a retrospective. JAMA Otolaryngol Head Neck Surg 2013; 139:446–453.
Cochlear Implants. National Institute on Deafness and other Communication Disorders; 2017. Available at: Https://www.nidcd.nih.gov/health/cochlear-implants. Accessed December 15, 2019.
Cochlear Nucleus Implant Reliability Report. Volume 17 | December 2018. D1593476. Cochlear Ltd; 2019.
2018 Global Reliability Report. 027-N025-02 Rev B. Advanced Bionics AG and Affiliates; 2018.
Hearing Implant Reliability Reporting | MEDEL [Internet]. MedEl.com; 2018. Available at: https://www.medel.com/us/reliabilityreporting. Accessed December 15, 2019.
Lassig AD, Zwolan TA, Telian SA. Implant failures and revision. Otol Neurotol 2005; 26:624–634.
Oliver ER, Gardner AM, Hashisaki GT. Revision cochlear implantation. Operat Tech Otolaryngol Head Neck Surg 2010; 21:261–265.
Chung D, Kim AH, Parisier S, et al. Revision cochlear implant surgery in patients with suspected soft failures. Otol Neurotol 2010; 31:1194–1198.
Karamert R, Düzlü M, Tutar H, et al. Assessment of cochlear implant revision surgeries in a cohort of 802 patients. Otol Neurotol 2019; 40:464–470.
Wang JT, Wang AY, Psarros C, Da Cruz M. Rates of revision and device failure in cochlear implant surgery: a 30-year experience. Otol Neurotol 2014; 124:2393–2399.
European consensus statement on cochlear implant failures and explantations. Otol Neurotol 2005;26:1097–9.
Balkany TJ, Hodges AV, Buchman CA. Cochlear implant soft failures consensus development conference statement. Otol Neurotol 2005; 26:815–818.
Peterson GE, Lehiste I. Revised CNC lists for auditory tests. J Speech Hear Disord 1962; 27:62–70.
Spahr AJ, Dorman MF. Performance of subjects fit with the Advanced Bionics CII and Nucleus 3G cochlear implant devices. Arch Otolaryngol Head Neck Surg 2004; 130:624–628.
Rivas A, Marlowe AL, Chinnici JE, Niparko JK, Francis HW. Revision cochlear implantation surgery in adults: indications and results. Otol Neurotol 2008; 29:639–648.
Marlowe AL, Chinnici JE, Rivas A. Revision cochlear implant surgery in children: the Johns Hopkins experience. Otol Neurotol 2010; 31:74–82.
Cullen RD, Fayad JN, Luxford WM, Buchman CA. Revision cochlear implant surgery in children. Otol Neurotol 2008; 29:214–220.
Stevens SM, Dougherty H, Wenstrup L, et al. Is hard failure still a common indication for revision surgery in adult cochlear implant recipients? Otol Neurotol 2019; 40:321–327.
Rivas A, Wanna G, Haynes D. Revision cochlear implantation in children. Otolaryngol Clin North Am 2012; 45:205–219.
Ulanoyski D, Attias J, Sokolov M, Greenstein T, Rayeh E. Pediatric cochlear implant soft failure. Am J Otolaryngol 2018; 39:107–110.

Auteurs

Kyle S Kimura (KS)

Department of Otolaryngology - Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH